Increased detection of (leukemiaspecific) adaptive and innate immune-reactive cells under treatment of AML-diseased rats and one therapy-refractory AML-patient with blastmodulating, clinically approved response modifiers. (March 2019) - Atzler, M.; Rank, A.; Inngjerdingen, M.; Rabe, A.; Deen, D.; Wang, R.; Eiz-Vesper, B.; Schmid, C.; Schmetzer, H.